A Phase II, Non-comparative, Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen

Trial Profile

A Phase II, Non-comparative, Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ATLANTIC
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Jun 2017 Results assessing correlation between pretreatment liver metastases and survival in durvalumab treated non-small cell lung cancer patients in two independent clinical trials (CP1108/NCT01693562 and ATLANTIC/NCT02087423), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2017 Results (n=600) of analysis assessing potential correlations of longitudinal changes in albumin and neutrophil lymphocyte ration and durvalumab clearance (CL) rate to maximum decrease in tumor size and overall survival using patient data from Study 1108 and ATLANTIC trials, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Results of post hoc pooled analysis of this and other phase 1/2 study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top